lidocaine has been researched along with Liver Cirrhosis in 67 studies
Lidocaine: A local anesthetic and cardiac depressant used as an antiarrhythmia agent. Its actions are more intense and its effects more prolonged than those of PROCAINE but its duration of action is shorter than that of BUPIVACAINE or PRILOCAINE.
lidocaine : The monocarboxylic acid amide resulting from the formal condensation of N,N-diethylglycine with 2,6-dimethylaniline.
Liver Cirrhosis: Liver disease in which the normal microcirculation, the gross vascular anatomy, and the hepatic architecture have been variably destroyed and altered with fibrous septa surrounding regenerated or regenerating parenchymal nodules.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Liver cirrhosis was produced in rats by intra-abdominal injection of thioacetamide." | 7.71 | Reassessment of monoethylglycinexylidide as preoperative liver function test in a rat model of liver cirrhosis and man. ( Ishii, T; Kaneko, H; Katagiri, M; Maeda, T; Otsuka, Y; Shiba, T; Takagi, S; Tamura, A; Tsuchiya, M, 2001) |
| "Serum leptin levels were determined by radioimmunoassay in 30 male and 10 female patients with chronic hepatitis, in 42 male and 10 female patients with liver cirrhosis, and in four respective control groups." | 7.70 | Serum leptin levels in patients with viral chronic hepatitis or liver cirrhosis. ( Barreca, T; Botta, F; Cataldi, A; Fasoli, A; Franceschini, R; Giannini, E; Rolandi, E; Tenerelli, P; Testa, R, 2000) |
| "Lidocaine (LID) is an aminoethylamide used in hepatology to perform the monoethylglycinexylidide (MEGX) test for the evaluation of liver function in patients with cirrhosis (CIR) or chronic hepatitis (CH)." | 7.70 | The monoethylglycinexylidide test does not impair psychometric performance in patients with chronic hepatitis or cirrhosis. ( Botta, F; Fasoli, A; Giannini, E; Risso, D; Romagnoli, P; Testa, R, 2000) |
| " After oral lidocaine, cirrhotic patients has a longer time to peak concentration (Tmax) and elimination half-life (t1/2), and a higher area under the curve (AUC)." | 6.68 | Pharmacokinetics of oral lidocaine and nifedipine in patients with liver cirrhosis. ( Klangwarnwong, D; Manorot, M; Praisontarangkul, OA; Tonsuwannont, W, 1996) |
| "Etoposide dosage in patients with liver dysfunction remains controversial." | 5.30 | Pharmacokinetics of oral etoposide in patients with hepatocellular carcinoma. ( Aita, P; Boiocchi, M; Cannizzaro, R; Colussi, AM; Corona, G; Robieux, I; Sorio, R; Toffoli, G; Tumolo, S, 1999) |
| " In cirrhosis the bioavailability of a flow-dependent drug increases because of both portosystemic shunting and hepatocyte dysfunction." | 5.27 | Disposition of a flow-limited drug (lidocaine) and a metabolic capacity-limited drug (theophylline) in liver cirrhosis. ( Buccino, G; Cocciolo, M; Colli, A; Parravicini, R; Scaltrini, G, 1988) |
| " In smokers, L systemic bioavailability was decreased secondary to a marked increase in oral clearance, reflecting induction of drug-metabolizing activity." | 5.26 | Effects of smoking and chronic hepatitis B on lidocaine and indocyanine green kinetics. ( Huet, PM; Lelorier, J, 1980) |
| "To evaluate the role played by the immune system in the outcome of chronic C virus infection, we studied the peripheral blood lymphocyte subsets in patients with chronic hepatitis C and the correlation with the hepatic function assessed by the lidocaine test." | 5.08 | [The peripheral blood lymphocyte subpopulations in chronic anti-HCV-positive liver disease: their significance and correlation with liver function]. ( Biceglia, O; De Biasio, MC; De Crescenzo, OD; Forte, GB; Minerva, A; Paceli, M; Rocco, P, 1996) |
| " In case of liver cirrhosis, only Child-Pugh-Turcott A patients with normal bilirubin levels and without portal hypertension should be considered for liver resection." | 4.84 | [Liver function test to predict hepatic failure after liver resection--expensive and without clinical relevance?]. ( Galle, PR; Kanzler, S; Teufel, A, 2007) |
| "The predicted versus observed plasma concentration-time profiles for alfentanil and lidocaine were similar, such that the pharmacokinetic changes associated with Child-Pugh class A, B and C liver cirrhosis were adequately described." | 3.74 | Physiology-based simulations of a pathological condition: prediction of pharmacokinetics in patients with liver cirrhosis. ( Edginton, AN; Willmann, S, 2008) |
| "Liver cirrhosis was produced in rats by intra-abdominal injection of thioacetamide." | 3.71 | Reassessment of monoethylglycinexylidide as preoperative liver function test in a rat model of liver cirrhosis and man. ( Ishii, T; Kaneko, H; Katagiri, M; Maeda, T; Otsuka, Y; Shiba, T; Takagi, S; Tamura, A; Tsuchiya, M, 2001) |
| "Thirty-five patients with liver cirrhosis of various aetiologies, who underwent monoethylglycinexylidide and 13C-galactose breath tests, were retrospectively evaluated for H." | 3.71 | Impairment of cytochrome P-450-dependent liver activity in cirrhotic patients with Helicobacter pylori infection. ( Borro, P; Botta, F; Chiarbonello, B; Fasoli, A; Fumagalli, A; Giannini, E; Malfatti, F; Polegato, S; Romagnoli, P; Savarino, V; Testa, E; Testa, R, 2001) |
| "The lidocaine (MEGX [monoethylglycinexylidide]) test, which was performed in 200 patients with different liver diseases and in 23 organ donors, was compared with common laboratory tests." | 3.70 | The lidocaine (MEGX) test as an index of hepatic function: its clinical usefulness in liver surgery. ( Callivà, R; Cavallari, A; Cescon, M; Ercolani, G; Grazi, GL; Mazziotti, A; Pierangeli, F, 2000) |
| "Serum leptin levels were determined by radioimmunoassay in 30 male and 10 female patients with chronic hepatitis, in 42 male and 10 female patients with liver cirrhosis, and in four respective control groups." | 3.70 | Serum leptin levels in patients with viral chronic hepatitis or liver cirrhosis. ( Barreca, T; Botta, F; Cataldi, A; Fasoli, A; Franceschini, R; Giannini, E; Rolandi, E; Tenerelli, P; Testa, R, 2000) |
| "Lidocaine (LID) is an aminoethylamide used in hepatology to perform the monoethylglycinexylidide (MEGX) test for the evaluation of liver function in patients with cirrhosis (CIR) or chronic hepatitis (CH)." | 3.70 | The monoethylglycinexylidide test does not impair psychometric performance in patients with chronic hepatitis or cirrhosis. ( Botta, F; Fasoli, A; Giannini, E; Risso, D; Romagnoli, P; Testa, R, 2000) |
| "Patients with acute hepatitis and patients with compensated or decompensated cirrhosis of the liver have a decreased plasma clearance of hexobarbital." | 3.66 | [Drug metabolism in patients with liver disease (author's transl)]. ( Epping, J; Fuchshofen-Röckel, M; Heusler, H; Richter, E; Zilly, W, 1980) |
| "Only in patients with Child's grade C liver cirrhosis were lignocaine kinetic parameters significantly altered with respect to healthy volunteers." | 2.71 | Effect of the CYP3A4 inhibitor erythromycin on the pharmacokinetics of lignocaine and its pharmacologically active metabolites in subjects with normal and impaired liver function. ( De Martin, S; Orlando, R; Padrini, R; Palatini, P; Piccoli, P, 2003) |
| "Lidocaine clearance was decreased on average by 60% (from 12." | 2.71 | Cytochrome P450 1A2 is a major determinant of lidocaine metabolism in vivo: effects of liver function. ( De Martin, S; Floreani, M; Orlando, R; Padrini, R; Palatini, P; Piccoli, P, 2004) |
| " After oral lidocaine, cirrhotic patients has a longer time to peak concentration (Tmax) and elimination half-life (t1/2), and a higher area under the curve (AUC)." | 2.68 | Pharmacokinetics of oral lidocaine and nifedipine in patients with liver cirrhosis. ( Klangwarnwong, D; Manorot, M; Praisontarangkul, OA; Tonsuwannont, W, 1996) |
| " Pharmacokinetic and pharmacodynamic changes depend on the nature and degree of hepatic impairment and on the characteristics of the dosed drug." | 2.49 | [Effect of liver cirrhosis on pharmacokinetics and pharmacodynamics of drugs]. ( Perlík, F, 2013) |
| " The patient's central nervous system symptoms were mild and transient but remind us that to avoid adverse side effects, orally administered drugs with fairly high hepatic extraction ratio given to patients with chronic liver disease need to be given in reduced dosages." | 1.39 | Even 'safe' medications need to be administered with care. ( Dill, C; Gambetta, R; Howland, MA; Lutwak, N, 2013) |
| "Sixteen patients with hepatocellular carcinoma in cirrhotic livers were enrolled in this study." | 1.33 | Assessment of hepatic reserve for indication of hepatic resection: how I do it. ( Chen, MF; Lee, WC, 2005) |
| "Etoposide dosage in patients with liver dysfunction remains controversial." | 1.30 | Pharmacokinetics of oral etoposide in patients with hepatocellular carcinoma. ( Aita, P; Boiocchi, M; Cannizzaro, R; Colussi, AM; Corona, G; Robieux, I; Sorio, R; Toffoli, G; Tumolo, S, 1999) |
| "The association of schistosomal liver fibrosis with cirrhosis does not additionally influence MEGX formation." | 1.30 | Assessment of liver function by the MEGX test in patients with schistosomiasis and cirrhosis. ( Ahmed, AM; Ahmed, HA; Armstrong, VW; El Desoky, ES; Nafeh, MA; Oellerich, M; Schütz, E, 1999) |
| "Patients with liver cirrhosis of different aetiology showed significantly higher Lidocain plasma concentrations and lower MEGX values than patients with chronic non-cirrhotic liver disease." | 1.29 | [Lidocaine elimination and MEGX formation after oral lidocaine administration--a practicable test for assessment of quantitative liver function]. ( Bomhard, M; Dorer, J; Joeres, R; Keller, F; Klinker, H; Richter, E; Zilly, W, 1993) |
| "Although liver cirrhosis causes significant modifications of GHB disposition kinetics, the increase in t1/2 is not such as to cause drug accumulation on repetitive dosing." | 1.29 | Effect of moderate or severe liver dysfunction on the pharmacokinetics of gamma-hydroxybutyric acid. ( Ferrara, SD; Frison, G; Mazzo, M; Orlando, R; Padrini, R; Palatini, P; Tedeschi, L; Zordan, R, 1996) |
| " Propranolol bioavailability correlated with the diameter of the portal vein and was dependent on the size of oesophageal varices and the presence of cavernous transformation of the portal vein." | 1.28 | [Usefulness of the evaluation of blood supply and mass of the liver for predicting the rate of pharmacokinetics of lidocaine, propranolol and phenazone]. ( Becker, A; Bołdys, H; Hartleb, M; Kloc, T; Mańczyk, I, 1989) |
| " In one patient with active hepatic necrosis the terminal plasma half-life was 57." | 1.27 | Pharmacokinetics of tocainide in patients with combined hepatic and renal dysfunction. ( Endell, W; Oltmanns, D; Pottage, A, 1983) |
| " In cirrhosis the bioavailability of a flow-dependent drug increases because of both portosystemic shunting and hepatocyte dysfunction." | 1.27 | Disposition of a flow-limited drug (lidocaine) and a metabolic capacity-limited drug (theophylline) in liver cirrhosis. ( Buccino, G; Cocciolo, M; Colli, A; Parravicini, R; Scaltrini, G, 1988) |
| "05), whereas lidocaine intrinsic clearance remained unchanged; bioavailability increased from 0." | 1.27 | Effect of portacaval shunt on drug disposition in patients with cirrhosis. ( Huet, PM; Marleau, D; Pomier-Layrargues, G; Villeneuve, JP, 1986) |
| " In smokers, L systemic bioavailability was decreased secondary to a marked increase in oral clearance, reflecting induction of drug-metabolizing activity." | 1.26 | Effects of smoking and chronic hepatitis B on lidocaine and indocyanine green kinetics. ( Huet, PM; Lelorier, J, 1980) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 16 (23.88) | 18.7374 |
| 1990's | 33 (49.25) | 18.2507 |
| 2000's | 16 (23.88) | 29.6817 |
| 2010's | 2 (2.99) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Perlík, F | 1 |
| Edginton, AN | 1 |
| Willmann, S | 1 |
| Lutwak, N | 1 |
| Howland, MA | 1 |
| Gambetta, R | 1 |
| Dill, C | 1 |
| Botta, F | 7 |
| Giannini, E | 8 |
| Romagnoli, P | 4 |
| Fasoli, A | 6 |
| Malfatti, F | 2 |
| Chiarbonello, B | 2 |
| Testa, E | 2 |
| Risso, D | 6 |
| Colla, G | 1 |
| Testa, R | 9 |
| Orlando, R | 3 |
| Piccoli, P | 2 |
| De Martin, S | 2 |
| Padrini, R | 3 |
| Palatini, P | 3 |
| Zipprich, A | 1 |
| Steudel, N | 1 |
| Behrmann, C | 1 |
| Meiss, F | 1 |
| Sziegoleit, U | 1 |
| Fleig, WE | 1 |
| Kleber, G | 1 |
| Floreani, M | 1 |
| Lee, WC | 1 |
| Chen, MF | 1 |
| Addario, L | 1 |
| Scaglione, G | 1 |
| Tritto, G | 1 |
| Di Costanzo, GG | 1 |
| De Luca, M | 1 |
| Lampasi, F | 1 |
| Galeota Lanza, A | 1 |
| Picciotto, FP | 1 |
| Tartaglione, MT | 1 |
| Utech, W | 1 |
| Macr, M | 1 |
| Giannelli, E | 1 |
| Ascione, A | 1 |
| Kanzler, S | 1 |
| Teufel, A | 1 |
| Galle, PR | 1 |
| Selden, R | 1 |
| Sasahara, AA | 1 |
| Oltmanns, D | 1 |
| Pottage, A | 1 |
| Endell, W | 1 |
| Huet, PM | 4 |
| Lelorier, J | 1 |
| Richter, E | 3 |
| Epping, J | 2 |
| Fuchshofen-Röckel, M | 1 |
| Heusler, H | 1 |
| Zilly, W | 3 |
| Klinker, H | 1 |
| Joeres, R | 1 |
| Bomhard, M | 1 |
| Keller, F | 1 |
| Dorer, J | 1 |
| Fabbri, A | 1 |
| Bianchi, GP | 1 |
| Marchesini, G | 1 |
| Reichel, C | 2 |
| Wienkoop, G | 2 |
| Nacke, A | 2 |
| Spengler, U | 2 |
| Forte, G | 1 |
| Rocco, P | 2 |
| Costanzo, A | 1 |
| Grimaldi, E | 1 |
| Rossi, R | 1 |
| Bottiglieri, ME | 1 |
| Biceglia, O | 2 |
| Zampella, G | 1 |
| Borzone, S | 1 |
| Campo, N | 2 |
| Alvarez, S | 2 |
| Caglieris, S | 3 |
| Arzani, L | 2 |
| Lantieri, PB | 4 |
| Celle, G | 4 |
| Arrigoni, A | 1 |
| Gindro, T | 1 |
| Aimo, G | 1 |
| Cappello, N | 1 |
| Meloni, A | 1 |
| Benedetti, P | 1 |
| Molino, GP | 1 |
| Verme, G | 1 |
| Rizzetto, M | 1 |
| Shiffman, ML | 4 |
| Luketic, VA | 4 |
| Sanyal, AJ | 5 |
| Duckworth, PF | 1 |
| Purdum, PP | 3 |
| Contos, MJ | 1 |
| Mills, AS | 1 |
| Edinboro, LE | 2 |
| Poklis, A | 1 |
| Wildgrube, HJ | 1 |
| Pritchard-Davies, R | 1 |
| Gross, AS | 1 |
| Shenfield, GM | 1 |
| Huang, YS | 1 |
| Lee, SD | 1 |
| Deng, JF | 1 |
| Wu, JC | 1 |
| Lu, RH | 1 |
| Lin, YF | 1 |
| Wang, YJ | 1 |
| Lo, KJ | 1 |
| Fisher, RA | 2 |
| Posner, MP | 2 |
| Oellerich, M | 5 |
| Hartmann, H | 1 |
| Ringe, B | 2 |
| Burdelski, M | 4 |
| Lautz, HU | 3 |
| Pichlmayr, R | 3 |
| Raymond, P | 1 |
| Tonsuwannont, W | 1 |
| Praisontarangkul, OA | 1 |
| Manorot, M | 1 |
| Klangwarnwong, D | 1 |
| Ferrara, SD | 1 |
| Tedeschi, L | 1 |
| Frison, G | 1 |
| Mazzo, M | 1 |
| Zordan, R | 1 |
| Thompson, EB | 1 |
| Paceli, M | 1 |
| Minerva, A | 1 |
| De Biasio, MC | 1 |
| De Crescenzo, OD | 1 |
| Forte, GB | 1 |
| Sudhop, T | 1 |
| Lüers, C | 1 |
| Hahn, C | 1 |
| Pohl, C | 1 |
| Sauerbruch, T | 1 |
| Laroche, N | 1 |
| Leneveu, A | 1 |
| Roux, A | 1 |
| Flouvat, B | 1 |
| Fabris, L | 1 |
| Jemmolo, RM | 1 |
| Toffolo, G | 1 |
| Paleari, D | 1 |
| Viaggi, S | 1 |
| Rigon, M | 1 |
| Casagrande, F | 1 |
| Lirussi, F | 1 |
| Strazzabosco, M | 1 |
| Cobelli, C | 1 |
| Okolicsanyi, L | 1 |
| Aita, P | 1 |
| Robieux, I | 1 |
| Sorio, R | 1 |
| Tumolo, S | 1 |
| Corona, G | 1 |
| Cannizzaro, R | 1 |
| Colussi, AM | 1 |
| Boiocchi, M | 1 |
| Toffoli, G | 1 |
| Muñoz, AE | 1 |
| Miguez, C | 1 |
| Rubio, M | 1 |
| Bartellini, M | 1 |
| Levi, D | 1 |
| Podestá, A | 1 |
| Niselman, V | 1 |
| Terg, R | 1 |
| Lluch Fernández, M | 1 |
| Vallejo Uclés, A | 1 |
| Vallejo Cantarero, F | 1 |
| Zurita Castro, F | 1 |
| Huelva Ramírez, E | 1 |
| Moreno Carmona, C | 1 |
| El Desoky, ES | 1 |
| Ahmed, AM | 1 |
| Nafeh, MA | 1 |
| Ahmed, HA | 1 |
| Schütz, E | 1 |
| Armstrong, VW | 1 |
| Ceppa, P | 1 |
| Valente, U | 1 |
| Dardano, G | 1 |
| Ercolani, G | 1 |
| Grazi, GL | 1 |
| Callivà, R | 1 |
| Pierangeli, F | 1 |
| Cescon, M | 1 |
| Cavallari, A | 1 |
| Mazziotti, A | 1 |
| Franceschini, R | 1 |
| Cataldi, A | 1 |
| Tenerelli, P | 1 |
| Rolandi, E | 1 |
| Barreca, T | 1 |
| Ol'rikh, M | 1 |
| Kukes, VG | 1 |
| Igonin, AA | 1 |
| Corpataux, JM | 1 |
| Munafo, A | 1 |
| Buclin, T | 1 |
| Biollaz, J | 1 |
| Mosimann, F | 1 |
| Kaneko, H | 1 |
| Otsuka, Y | 1 |
| Katagiri, M | 1 |
| Maeda, T | 1 |
| Tsuchiya, M | 1 |
| Tamura, A | 1 |
| Ishii, T | 1 |
| Takagi, S | 1 |
| Shiba, T | 1 |
| Borro, P | 1 |
| Fumagalli, A | 1 |
| Polegato, S | 1 |
| Savarino, V | 1 |
| Fuchshofen, M | 1 |
| Stremmel, W | 1 |
| Wojdat, R | 1 |
| Groteguth, R | 1 |
| Zoedler, M | 1 |
| Ebener, T | 1 |
| Niederau, C | 1 |
| Becker, H | 1 |
| Strohmeyer, G | 1 |
| Zfass, AM | 1 |
| Meyer, B | 1 |
| Luo, HS | 1 |
| Bargetzi, M | 1 |
| Renner, EL | 1 |
| Stalder, GA | 1 |
| Binder, L | 1 |
| Barry, M | 1 |
| Keeling, PW | 1 |
| Weir, D | 1 |
| Feely, J | 1 |
| Schulz, M | 2 |
| Schmidt, FW | 2 |
| Herrmann, H | 1 |
| Hartleb, M | 1 |
| Kloc, T | 1 |
| Mańczyk, I | 1 |
| Becker, A | 1 |
| Bołdys, H | 1 |
| Colli, A | 1 |
| Buccino, G | 1 |
| Cocciolo, M | 1 |
| Parravicini, R | 1 |
| Scaltrini, G | 1 |
| Raude, E | 1 |
| Lamesch, P | 1 |
| Raith, H | 1 |
| Scheruhn, M | 1 |
| Villeneuve, JP | 2 |
| Thibeault, MJ | 1 |
| Ampelas, M | 1 |
| Fortunet-Fouin, H | 1 |
| LaMarre, L | 1 |
| Côté, J | 1 |
| Pomier-Layrargues, G | 2 |
| Marleau, D | 1 |
| Varin, F | 1 |
| Mainous, EG | 1 |
| Boyne, J | 1 |
| Dunn, GD | 1 |
| Hayes, P | 1 |
| Breen, KJ | 1 |
| Schenker, S | 1 |
| Black, M | 1 |
| Thomson, PD | 1 |
| Melmon, KL | 1 |
| Richardson, JA | 1 |
| Cohn, K | 1 |
| Steinbrunn, W | 1 |
| Cudihee, R | 1 |
| Rowland, M | 1 |
| Clauss, RH | 1 |
| Breed, ES | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Sugammadex Versus Neostigmine for Antagonism of Rocuronium-induced Neuromuscular Blockade in Patients With Liver Cirrhosis Undergoing Liver Resection: A Controlled Randomized Study[NCT02414880] | Phase 4 | 60 participants (Actual) | Interventional | 2014-12-31 | Completed | ||
| Development of a Breath Test for Monitoring Liver Metabolic Function in Patients With Chronic Liver Disease and Cirrhosis[NCT00244569] | Phase 3 | 120 participants (Anticipated) | Interventional | 2005-09-30 | Completed | ||
| Maternal-Fetal Monitoring of Patients With Rheumatic Heart Disease During Dental Procedure Under Local Anesthesia[NCT00482573] | Phase 1 | 31 participants (Actual) | Interventional | 2004-04-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
5 reviews available for lidocaine and Liver Cirrhosis
| Article | Year |
|---|---|
[Effect of liver cirrhosis on pharmacokinetics and pharmacodynamics of drugs].
Topics: Analgesics; Anesthetics, Local; Anti-Arrhythmia Agents; Antihypertensive Agents; Hepatic Insufficien | 2013 |
[Liver function test to predict hepatic failure after liver resection--expensive and without clinical relevance?].
Topics: Bilirubin; Disease Progression; Hepatectomy; Humans; Indocyanine Green; Lidocaine; Liver; Liver Cirr | 2007 |
[Monoethylglycinexylidide (MEGX)-test. A test for the assessment of prognosis before and after liver transplantation].
Topics: Fluorescence Polarization Immunoassay; Hepatitis, Chronic; Humans; Lidocaine; Liver; Liver Cirrhosis | 1995 |
The liver in congestive heart failure: a review.
Topics: Alkaline Phosphatase; Anticoagulants; Ascites; Bilirubin; Digitalis Glycosides; Diuretics; Heart Fai | 1973 |
Liver disease and drug therapy.
Topics: Amobarbital; Azathioprine; Half-Life; Humans; Lidocaine; Liver Cirrhosis; Liver Diseases; Metabolic | 1974 |
10 trials available for lidocaine and Liver Cirrhosis
| Article | Year |
|---|---|
Effect of the CYP3A4 inhibitor erythromycin on the pharmacokinetics of lignocaine and its pharmacologically active metabolites in subjects with normal and impaired liver function.
Topics: Adult; Anesthetics, Local; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Double-Blind | 2003 |
Cytochrome P450 1A2 is a major determinant of lidocaine metabolism in vivo: effects of liver function.
Topics: Anti-Arrhythmia Agents; Area Under Curve; Cross-Over Studies; Cytochrome P-450 CYP1A2 Inhibitors; Do | 2004 |
Monoethylglycinexylidide formation in compensated cirrhosis: correlation with Child-Pugh score.
Topics: Adult; Aged; Analysis of Variance; Contraindications; Female; Humans; Lidocaine; Liver Cirrhosis; Li | 1994 |
The effect of liver disease and food on plasma MEGX concentrations.
Topics: Adult; Aged; Aging; Eating; Female; Humans; Injections, Intravenous; Lidocaine; Liver Cirrhosis; Liv | 1994 |
Measuring lidocaine metabolite--monoethylglycinexylidide as a quantitative index of hepatic function in adults with chronic hepatitis and cirrhosis.
Topics: Adult; Chronic Disease; Female; Follow-Up Studies; Galactose; Hepatitis; Humans; Indocyanine Green; | 1993 |
Pharmacokinetics of oral lidocaine and nifedipine in patients with liver cirrhosis.
Topics: Administration, Oral; Adult; Anesthetics; Cross-Over Studies; Female; Hemodynamics; Humans; Lidocain | 1996 |
[The peripheral blood lymphocyte subpopulations in chronic anti-HCV-positive liver disease: their significance and correlation with liver function].
Topics: Adult; Biopsy; Female; Hepatitis C; Hepatitis, Chronic; Humans; Lidocaine; Liver; Liver Cirrhosis; L | 1996 |
The low-dose monoethylglycinexylidide test: assessment of liver function with fewer side effects.
Topics: Adult; Aged; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Injections, Intr | 1997 |
Lidocaine and monoethylglycinexylidide serum determinations to analyze liver function of cirrhotic patients after oral administration.
Topics: Administration, Oral; Adult; Analysis of Variance; Area Under Curve; Bilirubin; Female; Half-Life; H | 1999 |
A preliminary evaluation of the discriminative power of the monoethylglycinexylidide formation test after intravenous and oral administration of lidocaine.
Topics: Administration, Oral; Area Under Curve; Diagnosis, Differential; Female; Half-Life; Humans; Infusion | 2001 |
52 other studies available for lidocaine and Liver Cirrhosis
| Article | Year |
|---|---|
Physiology-based simulations of a pathological condition: prediction of pharmacokinetics in patients with liver cirrhosis.
Topics: Alfentanil; Humans; Levetiracetam; Lidocaine; Liver Cirrhosis; Models, Biological; Piracetam; Theoph | 2008 |
Even 'safe' medications need to be administered with care.
Topics: Anesthetics, Local; Ataxia; Diplopia; Humans; Lidocaine; Liver Cirrhosis; Male; Middle Aged | 2013 |
MELD scoring system is useful for predicting prognosis in patients with liver cirrhosis and is correlated with residual liver function: a European study.
Topics: Adult; Aged; Epidemiologic Methods; Female; Humans; Lidocaine; Liver; Liver Cirrhosis; Liver Functio | 2003 |
Functional significance of hepatic arterial flow reserve in patients with cirrhosis.
Topics: Adenosine; Adult; Blood Flow Velocity; Blood Volume; Coloring Agents; Female; Galactose; Hepatic Art | 2003 |
Assessment of hepatic reserve for indication of hepatic resection: how I do it.
Topics: Carcinoma, Hepatocellular; Female; Hepatectomy; Humans; Lidocaine; Liver Cirrhosis; Liver Failure; L | 2005 |
Prognostic value of quantitative liver function tests in viral cirrhosis: a prospective study.
Topics: Adult; Disease Progression; Epidemiologic Methods; Female; Galactose; Hepatitis, Viral, Human; Human | 2006 |
Central nervous system toxicity induced by lidocaine. Report of a case in a patient with liver disease.
Topics: Adult; Central Nervous System Diseases; Humans; Injections, Intravenous; Lidocaine; Liver Cirrhosis; | 1967 |
Pharmacokinetics of tocainide in patients with combined hepatic and renal dysfunction.
Topics: Adult; Aged; Creatinine; Half-Life; Humans; Infusions, Parenteral; Kidney Diseases; Kinetics; Lidoca | 1983 |
Effects of smoking and chronic hepatitis B on lidocaine and indocyanine green kinetics.
Topics: Administration, Oral; Adult; Biological Availability; Chronic Disease; Female; Hepatitis B; Humans; | 1980 |
[Drug metabolism in patients with liver disease (author's transl)].
Topics: Acute Disease; Adult; Antipyrine; Biological Availability; Biotransformation; Cholestasis; Female; H | 1980 |
[Lidocaine elimination and MEGX formation after oral lidocaine administration--a practicable test for assessment of quantitative liver function].
Topics: Administration, Oral; Humans; Lidocaine; Liver Cirrhosis; Liver Diseases; Liver Function Tests; Meta | 1993 |
Hepatic lidocaine metabolism and liver histology.
Topics: Humans; Lidocaine; Liver; Liver Cirrhosis; Liver Function Tests; Sensitivity and Specificity | 1995 |
Monoethylglycinexylidide production as a measure in predicting hepatic histology.
Topics: Adult; Biomarkers; Female; Hepatitis, Chronic; Humans; Injections, Intravenous; Lidocaine; Liver Cir | 1994 |
Monoethylglicinexylidide test: a prognostic indicator of survival in cirrhosis.
Topics: Adult; Female; Follow-Up Studies; Humans; Lidocaine; Life Tables; Liver Cirrhosis; Liver Function Te | 1994 |
Hepatic lidocaine metabolism and liver histology in patients with chronic hepatitis and cirrhosis.
Topics: Adult; Aged; Alanine Transaminase; Chronic Disease; Female; Hepatitis; Humans; Lidocaine; Liver; Liv | 1994 |
[Liver function: still no new knowledge].
Topics: Half-Life; Humans; Indocyanine Green; Lidocaine; Liver Cirrhosis; Liver Function Tests; Metabolic Cl | 1994 |
Hepatic lidocaine metabolism is useful in the selection of patients in need of liver transplantation.
Topics: Hepatitis; Humans; Lidocaine; Liver; Liver Cirrhosis; Liver Diseases; Liver Transplantation | 1993 |
Assessment of prognosis in transplant candidates by use of the Pugh-MEGX score.
Topics: Adult; Female; Humans; Lidocaine; Life Tables; Liver Cirrhosis; Liver Function Tests; Liver Transpla | 1993 |
Hepatic lidocaine metabolism and complications of cirrhosis. Implications for assessing patient priority for hepatic transplantation.
Topics: Adult; Aged; Contraindications; Humans; Lidocaine; Liver; Liver Cirrhosis; Liver Function Tests; Liv | 1993 |
Effect of moderate or severe liver dysfunction on the pharmacokinetics of gamma-hydroxybutyric acid.
Topics: Aged; Analysis of Variance; Anti-Inflammatory Agents, Non-Steroidal; Antipyrine; Humans; Hydroxybuty | 1996 |
Use of hepatic lidocaine metabolism to monitor patients with chronic liver disease.
Topics: Anesthetics, Local; Chronic Disease; Genetic Variation; Humans; Infusions, Intravenous; Lidocaine; L | 1996 |
Monoethylglycinexylidide formation measurement as a hepatic function test to assess severity of chronic liver disease.
Topics: Adolescent; Adult; Age Factors; Aged; Anesthetics, Local; Case-Control Studies; Diagnosis, Different | 1997 |
Capillary gas chromatographic method for the measurement of small concentrations of monoethylglycinexylidide and lidocaine in plasma.
Topics: Chromatography, Gas; Humans; Lidocaine; Liver; Liver Cirrhosis; Liver Function Tests; Reproducibilit | 1998 |
The monoethylglycinexylidide test for grading of liver cirrhosis.
Topics: Adult; Discriminant Analysis; Female; Humans; Lidocaine; Liver Cirrhosis; Liver Function Tests; Male | 1999 |
Pharmacokinetics of oral etoposide in patients with hepatocellular carcinoma.
Topics: Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Aspartate Aminotra | 1999 |
[Anesthesia and intraoperative treatment in 2 cases of simultaneous liver, pancreas, and kidney transplantation].
Topics: Adult; Anesthesia, General; Cardiomyopathy, Hypertrophic; Diabetes Mellitus, Type 1; Diabetic Nephro | 1999 |
Assessment of liver function by the MEGX test in patients with schistosomiasis and cirrhosis.
Topics: Adult; Aged; Case-Control Studies; Cohort Studies; Female; Humans; Lidocaine; Liver Cirrhosis; Liver | 1999 |
Progressive liver functional impairment is associated with an increase in AST/ALT ratio.
Topics: Adult; Alanine Transaminase; Aspartate Aminotransferases; Chronic Disease; Clinical Enzyme Tests; Di | 1999 |
Can the MEGX test and serum bile acids improve the prognostic ability of Child-Pugh's score in liver cirrhosis?
Topics: Adult; Aged; Bile Acids and Salts; Female; Humans; Lidocaine; Liver Cirrhosis; Liver Transplantation | 1999 |
The lidocaine (MEGX) test as an index of hepatic function: its clinical usefulness in liver surgery.
Topics: Adult; Aged; Alanine Transaminase; Aspartate Aminotransferases; Bilirubin; Carcinoma, Hepatocellular | 2000 |
Oral or intravenous lidocaine administration to perform megx test?
Topics: Administration, Oral; Diagnosis, Differential; Hepatitis; Humans; Infusions, Intravenous; Lidocaine; | 2000 |
Serum leptin levels in patients with viral chronic hepatitis or liver cirrhosis.
Topics: Adipose Tissue; Adult; Female; Hepatitis B, Chronic; Hepatitis C, Chronic; Humans; Leptin; Lidocaine | 2000 |
The monoethylglycinexylidide test does not impair psychometric performance in patients with chronic hepatitis or cirrhosis.
Topics: Adult; Aged; Female; Hepatic Encephalopathy; Hepatitis, Chronic; Humans; Lidocaine; Liver Cirrhosis; | 2000 |
[Role of lidocaine metabolism studies in the diagnosis of liver diseases].
Topics: Adult; Animals; Clinical Enzyme Tests; Critical Care; Diagnosis, Differential; Dogs; Female; Hepatit | 2000 |
Reassessment of monoethylglycinexylidide as preoperative liver function test in a rat model of liver cirrhosis and man.
Topics: Alanine Transaminase; Animals; Aspartate Aminotransferases; Bilirubin; Disease Models, Animal; Hepat | 2001 |
Impairment of cytochrome P-450-dependent liver activity in cirrhotic patients with Helicobacter pylori infection.
Topics: Aged; Breath Tests; Carbon Radioisotopes; Cytochrome P-450 Enzyme System; Female; Galactose; Helicob | 2001 |
[Pharmacokinetics of lidocaine after intravenous and oral administration in patients with liver cirrhosis].
Topics: Administration, Oral; Humans; Injections, Intravenous; Lidocaine; Liver; Liver Cirrhosis | 1978 |
[Liver function tests in a clinical comparison].
Topics: Cholinesterases; Factor V; Factor VII; Galactose; Hepatic Encephalopathy; Humans; Indocyanine Green; | 1992 |
MEGX: from bench to bedside.
Topics: Humans; Indocyanine Green; Lidocaine; Liver Cirrhosis; Liver Function Tests; Liver Transplantation; | 1992 |
Quantitation of intrinsic drug-metabolizing capacity in human liver biopsy specimens: support for the intact-hepatocyte theory.
Topics: Adrenergic beta-Antagonists; Ethanolamines; Hepatitis, Chronic; Humans; Lidocaine; Liver; Liver Cirr | 1991 |
Predictors of one-year pretransplant survival in patients with cirrhosis.
Topics: Humans; Indocyanine Green; Lidocaine; Liver Cirrhosis; Liver Function Tests; Liver Transplantation; | 1991 |
Severity of cirrhosis and the relationship of alpha 1-acid glycoprotein concentration to plasma protein binding of lidocaine.
Topics: Adult; Aged; Blood Proteins; Humans; Lidocaine; Liver; Liver Cirrhosis; Middle Aged; Orosomucoid; Pr | 1990 |
Lidocaine metabolite formation as a measure of liver function in patients with cirrhosis.
Topics: Adult; Aged; Female; Half-Life; Humans; Injections, Intravenous; Kinetics; Lidocaine; Liver; Liver C | 1990 |
[Usefulness of the evaluation of blood supply and mass of the liver for predicting the rate of pharmacokinetics of lidocaine, propranolol and phenazone].
Topics: Adult; Aged; Antipyrine; Female; Humans; Lidocaine; Liver; Liver Circulation; Liver Cirrhosis; Male; | 1989 |
Disposition of a flow-limited drug (lidocaine) and a metabolic capacity-limited drug (theophylline) in liver cirrhosis.
Topics: Adult; Aged; Female; Humans; Hypertension, Portal; Lidocaine; Liver Cirrhosis; Male; Metabolic Clear | 1988 |
Monoethylglycinexylidide formation kinetics: a novel approach to assessment of liver function.
Topics: Chromatography, High Pressure Liquid; Fluorescence Polarization; Humans; Injections, Intravenous; Ki | 1987 |
Drug disposition in patients with HBsAg-positive chronic liver disease.
Topics: Adult; Aminopyrine; Antipyrine; Female; Hepatitis; Hepatitis B Surface Antigens; Hepatitis, Chronic; | 1987 |
Effect of portacaval shunt on drug disposition in patients with cirrhosis.
Topics: Adult; Aged; Aminopyrine; Biological Availability; Breath Tests; Female; Humans; Indocyanine Green; | 1986 |
Hepatic microcirculation in the perfused cirrhotic rat liver.
Topics: Animals; Extracellular Space; Lidocaine; Liver; Liver Cirrhosis; Male; Microcirculation; Microsphere | 1985 |
Hepatic coma after multiple dental extractions: report of case.
Topics: Anesthesia, Local; Anti-Bacterial Agents; Epinephrine; Hepatic Encephalopathy; Humans; Hypnotics and | 1974 |
Lidocaine pharmacokinetics in advanced heart failure, liver disease, and renal failure in humans.
Topics: Adult; Alcoholism; Blood Proteins; Chromatography, Gas; Female; Half-Life; Heart Failure; Humans; In | 1973 |
Controlled rate of drainage of thoracic duct lymph.
Topics: Adult; Anesthesia, Local; Ascites; Catheterization; Drainage; Extracellular Space; Heart Failure; Hu | 1970 |